Presynaptic nicotinic acetylcholine receptors (nAChRs) on striatal synaptosomes stimulate dopamine release. Partial inhibition by the ␣3␤2-selective ␣-conotoxin-MII indicates heterogeneity of presynaptic nAChRs on dopamine terminals. We have used this ␣-conotoxin and UB-165, a novel hybrid of epibatidine and anatoxin-a, to address the hypothesis that the ␣-conotoxin-MII-insensitive subtype is composed of ␣4 and ␤2 subunits. UB-165 shows intermediate potency, compared with the parent molecules, at ␣4␤2* and ␣3-containing binding sites, and resembles epibatidine in its high discrimination of these sites over ␣7-type and muscle binding sites.
Presynaptic nicotinic acetylcholine receptors (nAChRs) on striatal synaptosomes stimulate dopamine release. Partial inhibition by the ␣3␤2-selective ␣-conotoxin-MII indicates heterogeneity of presynaptic nAChRs on dopamine terminals. We have used this ␣-conotoxin and UB-165, a novel hybrid of epibatidine and anatoxin-a, to address the hypothesis that the ␣-conotoxin-MII-insensitive subtype is composed of ␣4 and ␤2 subunits. UB-165 shows intermediate potency, compared with the parent molecules, at ␣4␤2* and ␣3-containing binding sites, and resembles epibatidine in its high discrimination of these sites over ␣7-type and muscle binding sites. (Ϯ)-Epibatidine, (Ϯ)-anatoxin-a, and (Ϯ)-UB-165 stimulated [ 3 H]-dopamine release from striatal synaptosomes with EC 50 values of 2.4, 134, and 88 nM, and relative efficacies of 1:0.4:0.2, respectively. ␣-Conotoxin-MII inhibited release evoked by these agonists by 48, 56, and 88%, respectively, suggesting that (Ϯ)-UB-165 is a very poor agonist at the ␣-conotoxin-MIIinsensitive nAChR subtype. In assays of 86 
Rb
ϩ efflux from thalamic synaptosomes, a model of an ␣4␤2* nAChR response, (Ϯ)-UB-165 was a very weak partial agonist; the low efficacy of (Ϯ)-UB-165 at ␣4␤2 nAChR was confirmed in Xenopus oocytes expressing various combinations of human nAChR subunits. In contrast, (Ϯ)-UB-165 and (Ϯ)-anatoxin-a were similarly efficacious and similarly sensitive to ␣-conotoxin-MII in increasing intracellular Ca 2ϩ in SH-SY5Y cells, a functional assay for native ␣3-containing nAChR. These data support the involvement of ␣4␤2* nAChR in the presynaptic modulation of striatal dopamine release and illustrate the utility of exploiting a novel partial agonist, together with a selective antagonist, to dissect the functional roles of nAChR subtypes in the brain.
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Nicotinic acetylcholine receptors (nAChRs) are widely distributed in the vertebrate CNS. With a few recently reported exceptions (Alkondon et al., 1998; Frazier et al., 1998) , most nAChRs in the brain do not appear to mediate synaptic transmission. Instead, their primary function may be modulatory (Role and Berg, 1996) . One locus for modulation is the nerve terminal, where presynaptic nAChRs can promote transmitter release and hence influence resting tone or synaptic efficacy.
Presynaptic nAChRs facilitate the release of many neurotransmitters, in numerous brain regions, via various nAChR subtypes (Wonnacott, 1997) . nAChR heterogeneity arises from the pentameric assembly of receptors from numerous ␣ and ␤ subunits (␣2-␣7, ␤2-␤4) expressed in the mammalian brain (Role and Berg, 1996; Lukas et al., 1999) . Defining the subunit composition of native nAChR is a major challenge; this quest is hampered by a lack of subtype-specific tools. A recent advance has been the identification of Conus toxins that target particular neuronal nAChR subtypes (McIntosh et al., 1999) . ␣-Conotoxin-MII, with specificity for ␣3␤2-containing nAChRs (Cartier et al., 1996) , partially inhibits the nicotinic stimulation of [ 3 H]-dopamine release from striatal preparations (Kulak et al., 1997; Kaiser et al., 1998) , indicating heterogeneity of the nAChR mediating this response.
The nicotinic modulation of [ 3 H]-dopamine release from striatal preparations has been exploited as a model system for examining native nAChR responses (Soliakov and Wonnacott, 1996; Grady et al., 1997) and evaluating novel ligands (Holladay et al., 1997) and is pertinent to physiological and pathological processes (Dani and Heinemann, 1996; Decker and Arneric, 1998) . Nicotinic agonists elicit dopamine release from rodent striatal synaptosomes and slices in a concentration-dependant manner, and this response is blocked by nicotinic antagonists, including mecamylamine and dihydro␤erythroidine (Grady et al., 1992; El-Bizri and Clarke, 1994; Sacaan et al., 1995; Soliakov et al., 1995) . Insensitivity to the ␣7-selective antagonists ␣-bungarotoxin (␣Bgt) (Rapier et al., 1990; Grady et al., 1992) and ␣-conotoxin-ImI (Kulak et al., 1997) argues against the direct involvement of ␣7 nAChR. The loss of [
3 H]-nicotine binding sites from the striatum after 6-hydroxy-dopamine lesion of the nigrostriatal pathway is consistent with ␣4␤2 nAChRs on striatal terminals (Clarke and Pert, 1985) . Alternatively, sensitivity to neuronal bungarotoxin was interpreted in favor of ␣3-containing nAChRs (Grady et al., 1992) . These disparate views are reconciled by the nAChR heterogeneity implicit in the partial inhibition by ␣-conotoxin-MII (Kulak et al., 1997; Kaiser et al., 1998) . The selectivity of this toxin is consistent with an nAChR containing ␣3 and ␤2 subunits (Cartier et al., 1996; Kaiser et al., 1998) ; the ␣4␤2* nAChR is a candidate for the ␣-conotoxin-MII-insensitive component of dopamine release evoked by nicotinic agonists.
Here we report studies with the novel nicotinic ligand UB-165 (Wright et al., 1997 ) (see Fig. 1 ) that support this interpretation. UB-165 is a hybrid of anatoxin-a and epibatidine, with potency at rat brain [
3 H]-nicotine binding sites that is intermediate between the values of the parent molecules. We have extended the characterization of UB-165 and have exploited its limited agonism at ␣4␤2 nAChRs to examine the putative contribution of this subtype to the nicotinic stimulation of striatal dopamine release.
MATERIALS AND METHODS Materials
Cell culture. SH-SY5Y cells were from European Collection of Animal C ell Cultures (Porton Down, Salisbury, Wiltshire, UK) and were cultured as described by Murphy et al. (1991) . M10 cells were provided by Dr. P. Whiting (Merck, Sharp and Dohme Research C enter, Harlow, Essex, UK) and were cultured as described previously (Whiteaker et al., 1998 86 RbC l was obtained from Dupont N EN (Herts, UK or Boston, M A); it was stored at 20°C and used within 1 month. [7, H]-dopamine (specific activity, 1.78 TBq /mmol) was purchased from Amersham International (Buckinghamshire, UK) and stored at Ϫ20°C. Na 125 I from Amersham International was used to iodinate ␣Bgt to a specific activity of 26 TBq /mmol. (Ϯ)-Epibatidine was purchased from RBI (Natick, M A), and (Ϯ)-anatoxin-a was obtained from Tocris Cookson (Bristol, UK). Racemic UB-165 (Wright et al., 1997) and ␣-conotoxin-M II (C artier et al., 1996; Kaiser et al., 1998) were synthesized as previously described. All other drugs and reagents were provided by Sigma (Poole, Dorset, UK).
Tissue preparations
Rat brain membranes. P2 membranes from whole rat brain (minus cerebellum) were prepared as previously described (Davies et al., 1999) . Briefly, brains were homogenized (10% w/ v) in ice-cold 0.32 M sucrose, pH 7.4, containing 1 mM EDTA, 0.1 mM PMSF, and 0.01% NaN 3 , and centrif uged at 1000 ϫ g for 10 min. The supernatant fraction (S1) was decanted and retained on ice. The pellet (P1) was resuspended in ice-cold 0.32 M sucrose (5 ml /g original weight) and recentrif uged at 1000 ϫ g for 10 min. The supernatant was combined with S1 and centrif uged at 12,000 ϫ g for 30 min. The pellet (P2) was resuspended (2.5 ml /g original weight) in phosphate buffer (50 mM potassium phosphate, pH 7.4, containing 1 mM EDTA, 0.1 mM PMSF, and 0.01% NaN 3 ), and washed twice by centrif ugation at 12,000 ϫ g for 30 min. The washed pellet was resuspended in phosphate buffer (2.5 ml /g original weight) and stored in 5 ml aliquots at Ϫ20°C.
Rat muscle e xtract preparation. A Triton X-100 extract of muscle from the hindlimbs of Wistar rats was prepared as previously described (Garcha et al., 1993) .
SH-SY5Y cell membrane preparation. SH-SY5Y cells, grown to confluency in 175 cm 2 flasks, were washed briefly with warm PBS containing (in mM): (150 NaC l, 8 K 2 HPO 4 , 2 KH 2 PO 4 , pH 7.4, 37°C) and scraped into cold phosphate buffer. C ells were washed by centrif ugation for 3 min at 500 ϫ g and resuspended in 10 ml of ice-cold phosphate buffer. The suspension was homogenized for 10 sec using an Ultraturax and centrif uged for 30 min at 45,000 ϫ g. The pellet was resuspended in phosphate buffer (0.5 ml per original flask).
Radioligand binding assays (Ϫ)-[
3 H]-nicotine competition binding assays: rat brain membranes. P2 membranes (250 g protein) were incubated in a total volume of 250 l in H EPES buffer (20 mM H EPES, pH 7.4, containing 118 mM NaC l, 4.8 mM KC l, 2.5 mM CaCl 2 , 200 mM Tris, 0.1 mM PMSF, 0.01% (w/ v) NaN 3 ) (Romm et al., 1990 ) with 10 nM (Ϫ)-[
3 H]-nicotine and serial dilutions of test drugs. Nonspecific binding was determined in the presence of 100 M (Ϫ)-nicotine. Samples were incubated for 30 min at room temperature followed by 1 hr at 4°C. The reaction was terminated by filtration through Whatman GFA / E filter paper (presoaked overnight in 0.3% polyethyleneimine in PBS), using a Brandel C ell Harvester. Filters were counted for radioactivity in 5 ml Optiphase "Safe" scintillant in a Packard Tricarb 1600 scintillation counter (counting efficiency 45%).
(Ϯ (Davies et al., 1999) . Nonspecific binding was determined in the presence of 10 M ␣Bgt. Samples were incubated for 3 hr at 37°C. Ice-cold PBS (0.5 ml) was then added, and the samples were centrif uged for 3 min at 10,000 ϫ g. Pellets were washed by resuspension in 1.25 ml PBS and centrif ugation as before. The resultant pellets were counted for radioactivity in a Packard Cobra II auto-gamma counter.
[ 125 I]-␣Bgt competition binding assays: rat muscle e xtract. Rat muscle extract (1.5 mg protein) was incubated in a total volume of 500 l in 2.5 mM sodium phosphate buffer, pH 7.4, with 1 nM [
125 I]-␣Bgt and serial dilutions of test drugs (Garcha et al., 1993) . Nonspecific binding was determined in the presence of 10 M ␣Bgt. Samples were incubated for 2 hr at 37°C. Bound radioligand was separated by filtration through Whatman GF/C filters (presoaked in 0.3% polyethyleneimine in PBS overnight) using a Millipore vacuum manifold. Filters were washed three times with 3 ml cold PBS supplemented with 0.1% BSA and counted for radioactivity in a Packard Cobra II auto-gamma counter. 3 H]-epibatidine for 2 hr, as previously described (Whiteaker et al., 1998 
Upregulation of [ 3 H]-epibatidine binding sites in M10 cells
M10 cells grown were grown in 24-well plates to ϳ70% confluency and were then incubated for 48 hr at 37°C with dexamethasone (to induce nAChR expression) in medium containing serial dilutions of test drugs (Whiteaker et al., 1998) . Control cells, treated with dexamethasone in medium without the addition of nicotinic agents, were incubated in parallel. A rigorous washing procedure, in which medium was replaced three times at hourly intervals, was used to ensure removal of nicotinic drugs (Whiteaker et al., 1998 ) before assaying for [ 3 H]-epibatidine binding sites as outlined above.
Superfusion of rat striatal synaptosomes for [ 3 H]-dopamine release
P2 synaptosomes were prepared from rat striata, loaded with [ 3 H]-dopamine (0.1 M, 0.132 MBq /ml) for 15 min at 37°C, and superf used in open chambers as previously described (Soliakov et al., 1995; Kaiser et al., 1998) . Synaptosomes were superf used with Krebs bicarbonate buffer containing (in mM): 118 NaC l, 2.4 KC l, 2.4 C aC l 2 , 1.2 MgSO 4 , 1.2 K 2 HPO 4 , 25 NaHC O 3 and 10 glucose, titrated to pH 7.4 with 95% O 2 /5% CO 2 , supplemented with 1 mM ascorbic acid, 8 M pargyline, and 0.5 M nomifensine to prevent dopamine degradation and reuptake. Agonists were applied for 40 sec. In antagonist studies, ␣-conotoxin-M II (112 nM) or mecamylamine (10 M) was added to the superf usion buffer 10 min before the application of agonist and maintained throughout the remainder of the experiment. E xperiments always included chambers stimu-lated in parallel with 1 M (Ϯ)-anatoxin-a, as a standard for normalization of data between experiments.
Rb
ϩ efflux from thalamic synaptosomes 86 Rb ϩ efflux experiments were performed essentially as described by Marks et al. (1996) . P2 synaptosomes were prepared from mouse or rat thalamus by homogenization in 0.32 M sucrose in 5 mM H EPES, pH 7.5, and differential centrif ugation (Soliakov et al., 1995) . Synaptosomes were loaded with 86 Rb ϩ (sufficient to give ϳ70 MBq per chamber) by incubation for 30 min at 22°C in uptake buffer containing (in mM): 140 NaC l, 1.5 KC l, 2.0 C aC l 2 , 1.0 MgS0 4 , 25 H EPES, 20 glucose, pH 7.5. Uptake was terminated, and unincorporated 86 Rb ϩ was removed by transferring aliquots (mouse, 25 l; rat, 35 l) to glass fiber filters for gentle filtration and washing. One thalamus provided sufficient material for up to 8 (mouse) or 12 (rat) filters. Each filter was placed in an open chamber of a superf usion apparatus (Marks et al., 1993; Soliakov et al., 1995) . Samples were perf used at a rate of 2.5 ml /min with physiological buffer [135 mM NaC l,, 1.5 mM KC l, 2.0 mM CaCl 2 , 1.0 mM MgS0 4 , 20 mM glucose, 25 mM H EPES, pH 7.5, containing 0.1% (w/ v) BSA; 5 mM CsCl and 50 nM tetrodotoxin]. After perf usion for 6 min, 12 samples were collected at 30 sec intervals. Agonist stimulation (60 sec) was given 90 sec after the start of sample collection. Where used, antagonists were present in the perf usion buffer throughout the experiment.
Xenopus oocyte preparation and recording
Stage V-V I oocytes were isolated from anesthetized Xenopus laevis frogs and enzymatically defolliculated by gentle shaking with collagenase [Worthington (Freehold, NJ), T ype II, 1.7 mg /ml for 90 min; then Sigma (St. L ouis, MO), T ype II, 1.7 mg /ml for 30 min] in a C a 2ϩ -free Barth's solution. After defolliculation, oocytes were incubated at 16 -19°C in a solution containing (in mM): 77.5 NaC l, 2 KC l, 1.8 C aC l 2 , 1 MgC l 2 , 5 H EPES, pH 7.5, adjusted with NaOH, and supplemented with 100 U/ml penicillin, 100 g /ml streptomycin, 50 mg /ml gentimycin, and 5% heatinactivated horse serum. Oocytes were injected the next day with 10 -50 ng of mRNA encoding ␣x and ␤x nAChR subunits in an injection volume of 50 nl. The human nAChR subunits ␣2, ␣3, ␣4 -2, ␤2, ␤4, and ␣7 were cloned from cDNA libraries prepared from human brain and the human IMR32 neuroblastoma cell line (Elliott et al., 1996) . For two-way combinations, RNA was injected at a ratio of 1:1 (25 ng of each subunit per egg). RNA for ␣7 was injected at a concentration of 25 ng per egg.
Oocytes were examined for f unctional expression 2-5 d after mRNA injection using two-electrode voltage-clamp techniques described previously (Chavez-Noriega et al., 1997). Agonist-induced currents were elicited at a holding potential of Ϫ60 mV. The recording solution contained (in mM): 115 NaC l, 2.5 KC l, 1.8 C aC l 2 , 10 H EPES, 0.001 atropine, pH 7.3. Recording electrodes (0.5-2.5 M⍀ resistance) were filled with 3 M KC l. Perf usion solutions were gravity fed into the recording chamber (capacity, 100 l) at a rate of ϳ6 -10 ml /min. All recordings were performed at room temperature (19 -23°C). Signals were amplified, digitized (100 -500 Hz), and filtered (at 40 -200 Hz).
Calcium fluorimetry
SH-SY5Y cells, grown to confluency in 175 cm 2 flasks, were removed by incubation in C a 2ϩ -free PBS for 3 min at 37°C. The cell suspension was centrif uged for 3 min at 500 ϫ g, and the pellet was resuspended in 3-4 ml Ca 2ϩ -free H EPES buffer containing (in mM): 145 NaC l, 5 KC l, 1 MgC l 2 , 0.5 Na 2 HPO 4 , 5.5 glucose, and 10 H EPES, pH 7.4, containing 5 M f ura-2 AM. The suspension was incubated in darkness at room temperature for 45 min, and excess f ura-2 AM was removed by centrifugation for 3 min at 500 ϫ g followed by three wash /centrif ugation steps. C ell density was adjusted to 1-2 ϫ 10 6 cells/ml, and a 2 ml aliquot of cell suspension was placed in a cuvette in a P TI dual-excitation spectrophotofluorimeter (Photon Technology International, South Brunswick, NJ). To the cell suspension, 2 mM CaCl 2 was added before applying a nicotinic agonist ((Ϯ)-UB-165 or (Ϯ)-anatoxin-a). Where used, the antagonist ␣-conotoxin-M II (112 nM) or mecamylamine (10 M) was added to the cuvette 5 min before the addition of agonist. E xcitation at 340 and 380 nm and emission at 510 nm were monitored. C alibration was performed in each experiment by adding sequentially 0.5% (v/ v) Triton X-100 and 10 mM EDTA to derive maximum and minimum fluorescence ratios, respectively. Results were normalized within each experiment with respect to a maximally stimulating concentration of agonist. (Marks et al., 1996) . Basal efflux was defined as cpm collected in the fractions immediately before and after stimulation, and the basal rate of 86 Rb ϩ efflux was determined as an exponentially decaying curve fitted to these data points. Agonist-stimulated efflux was calculated as the cpm above the calculated baseline during the period of agonist application. To correct for interexperimental variation in synaptosomal 86 Rb ϩ uptake, agoniststimulated efflux was divided by the calculated baseline efflux. Values for 86 Rb ϩ efflux from mouse thalamic synaptosomes are more than double those from corresponding rat preparations (see Fig. 5 ), reflecting the higher density of [ 3 H]-nicotine binding sites in mouse thalamus. Curve fitting of 86 Rb ϩ efflux data from mouse thalamic synaptosomes was performed using the nonlinear least squares curve fitting facility of Sigma Plot V5.0 for DOS.
Upregulation. Upregulation profiles were fit to a logistic equation (Whiteaker et al., 1998) using the nonlinear least squares curve fitting facility of Sigma Plot V2.0 for Windows, to give the EC 50 for the upward phase of the dose -response curve and U max , the maximum upregulation produced by the drug tested.
Dopamine release. Evoked [ 3 H]-dopamine release was calculated as the area under the peak, after subtraction of the baseline, as described previously (Kaiser et al., 1998) . Data points for agonist dose -response relationships (after subtraction of nonspecific release determined in the presence of mecamylamine) were fitted to the Hill equation y ϭ
where a is the asymptotic maximum, d is the asymptotic minimum, k is the agonist concentration at the inflection point (EC 50 ), x is the ligand concentration, and n is the slope parameter (Hill number).
Data for inhibition by antagonist are represented as percentages of the corresponding controls, assayed in parallel in the absence of antagonist. One-way ANOVA-post hoc Bonferroni test was used to determine the significance of differences from control.
Two-electrode voltage-clamp recordings. Full dose -response curves were obtained from individual oocytes and normalized relative to the response to an EC 50 concentration of ACh recorded in the same oocyte. Sigmoidal concentration -response curves were fit to the Hill equation using Origin 4.0 (Microcal Software).
Calcium fluorimetr y. The intracellular C a 2ϩ concentration ([C a 2ϩ ] i ) was calculated from the fluorescence ratio of f ura-2 (A 340 /A 380 , given as R below) according to the Grynkiewicz equation (Grynkiewicz et al., 1985) 
, where K d is the dissociation constant for C a 2ϩ binding to f ura-2, R min is the fluorescence ratio under nominally "zero" free C a 2ϩ conditions, R max is the fluorescence ratio under saturating C a 2ϩ conditions, and S f2 /S b2 is the ratio of fluorescence values of C a 2ϩ -free and C a 2ϩ -saturated f ura-2, measured at the wavelength used to monitor C a 2ϩ -free f ura-2. For dose -response curves, agonist responses were calculated as the percentage of the change in intracellular C a 2ϩ produced by a maximally stimulating concentration of the same agonist, assayed in parallel. EC 50 values were calculated by fitting data points to the Hill equation, using the nonlinear least squares curve fitting facility of Sigma Plot V2.0 for Windows.
RESULTS

Competition binding assays
(Ϯ)-UB-165 was compared with (Ϯ)-anatoxin-a and (Ϯ)-epibatidine (see Fig. 1 for structures) for its ability to displace the binding of a number of nicotinic radioligands (Fig. 2, Table 1 ). Radioligand binding assays, at least those using radiolabeled agonists, reflect the desensitized state of the nAChRs. Most high-affinity [ 3 H]-nicotine binding sites in rat brain are considered to represent the ␣4␤2 subtype (Zoli et al., 1998 (Fig. 2 B) .
[ 3 H]-Epibatidine labels ␣3-containing nAChRs in human neuroblastoma SH-SY5Y cells (Wang et al., 1996) . The concentration of [ 3 H]-epibatidine used (150 pM) was chosen to preferentially label ␣3␤2-containing nAChRs [including ␣3␤2 and ␣3␤2␣5 combinations (Wang et al., 1996) (Fig. 2C) . (Ϯ)-UB-165 was also examined for its ability to displace [ 125 I]-␣Bgt from rat muscle extract (Fig. 2 D) . Its K i value of 990 Ϯ 240 nM was similar to that of (Ϯ)-epibatidine (K i ϭ 610 Ϯ 160 nM), whereas (Ϯ)-anatoxin-a was the most potent competing ligand, with a K i value of 85 Ϯ 41 nM.
Thus the rank order of potencies at the rat and chicken ␣4␤2 and human ␣3-containing nAChR subtypes is (Ϯ)-epibatidine Ͼ (Ϯ)-UB-165 Ͼ (Ϯ)-anatoxin-a. In contrast, (Ϯ)-UB-165 was the least potent at ␣7-type nAChRs and muscle nAChRs: rank orders of potencies are (Ϯ)-epibatidine Ͼ (Ϯ)-anatoxin-a Ն (Ϯ)-UB-165 and (Ϯ)-anatoxin-a Ͼ (Ϯ)-epibatidine Ն (Ϯ)-UB-165, respectively. The ability of each of these ligands to discriminate between nAChR subtypes was expressed as an affinity ratio, relative to the value at the rat brain [
3 H]-nicotine binding site, which was defined as 1 (Table 1) . From comparison of these affinity ratios, (Ϯ)-UB-165 resembles (Ϯ)-epibatidine in its marked preference for ␣4␤2* nAChRs compared with ␣7-type and muscle nAChRs.
Upregulation of ␣4␤2 nAChRs
(Ϯ)-Epibatidine and (Ϯ)-anatoxin-a differ in their abilities to upregulate ␣4␤2 nAChRs in the M10 cell line: (Ϯ)-epibatidine is a partial upregulator whereas (Ϯ)-anatoxin-a is fully efficacious (Whiteaker et al., 1998) . (Ϯ)-UB-165 was compared with (Ϯ)-anatoxin-a and (Ϯ)-epibatidine in this assay, to determine which of the parent compounds it most resembles with respect to upregulation (Fig. 3) . Dose-response profiles for upregulation produced by (Ϯ)-UB-165 and (Ϯ)-anatoxin show that they are similarly efficacious, with maximum upregulation of 237 Ϯ 47 and 221 Ϯ 27% above control levels, respectively. (Ϯ)-UB-165 was a more potent upregulator than (Ϯ)-anatoxin-a, with EC 50 values of 25.3 Ϯ 17.7 and 985 Ϯ 515 nM, respectively. In contrast, (Ϯ)-epibatidine achieved a maximum upregulation of only 76 Ϯ 6% above control, although it was the most potent of the three ligands, with an EC 50 value of 1.2 Ϯ 0.2 nM. The ability of (Ϯ)-UB-165 to upregulate nicotinic binding sites is consistent with it behaving as an agonist at ␣4␤2 nAChRs, because all agonists that we have examined have produced some degree of upregulation in this system, whereas antagonists produce little if any upregulation (Whiteaker et al., 1998) .
Presynaptic nicotinic stimulation of [ 3 H]-dopamine release from rat striatal synaptosomes (Ϯ)-UB-165 was compared with (Ϯ)-anatoxin-a, (Ϯ)-epibatidine, and (Ϫ)-nicotine for their abilities to promote [
3 H]-dopamine release from rat striatal synaptosomes (Fig. 4 A) . Of these four compounds, (Ϯ)-epibatidine was the most efficacious and most potent (EC 50 value ϭ 2.42 Ϯ 0.44 nM), whereas (Ϫ)-nicotine (EC 50 value ϭ 1.59 Ϯ 0.38 M) was the least potent but had higher efficacy than (Ϯ)-anatoxin-a. Although (Ϯ)-UB-165 was slightly more potent than (Ϯ)-anatoxin-a (EC 50 values ϭ 88 Ϯ 18 and 134 Ϯ 26 nM, respectively), it was much less efficacious than the other agonists, achieving a maximum of specific, nAChRmediated [
3 H]-dopamine release that was only 42% of that of (Ϯ)-anatoxin-a and 21% of that of (Ϯ)-epibatidine.
nAChRs mediating the presynaptic nicotinic stimulation of [ 3 H]-dopamine release from striatal terminals appear to be heterogeneous, based on the partial inhibition by the ␣3␤2-selective toxin ␣-conotoxin-MII (Kulak et al., 1997; Kaiser et al., 1998) . A maximally effective concentration of this toxin (112 nM) was compared with mecamylamine (10 M) for their abilities to inhibit 
]-␣Bgt binding sites ( D) in rat muscle extract. Preparations were incubated with radioligand and increasing concentrations of (Ϯ)-UB-165 (OE), (Ϯ)-anatoxin-a (E), or (Ϯ)-epibatidine (Ⅺ) as described in Materials and Methods. Each point is the mean of at least three separate determinations Ϯ SEM. Data points were fitted to the Hill equation.
[
3 H]-dopamine release evoked by maximally effective concentrations of the four agonists mentioned above (Fig. 4 B) . The results confirm the differences in efficacy noted above. Although mecamylamine inhibited agonist-evoked [ 3 H]-dopamine release to the same extent in each case (the residual release being the nonspecific component that is elicited by a buffer pulse without agonist), ␣-conotoxin-MII produced varying degrees of inhibition. The mecamylamine-sensitive response to (Ϯ)-anatoxin-a was reduced by 56% by the toxin, in agreement with our previous findings (Kaiser et al., 1998) , whereas the mecamylaminesensitive [
3 H]-dopamine release evoked by (Ϯ)-epibatidine and (Ϫ)-nicotine was inhibited by 47.9 and 32.4%, respectively. However, the mecamylamine-sensitive response to (Ϯ)-UB-165 was almost completely blocked (87.8%) by ␣-conotoxin-MII. This suggests that (Ϯ)-UB-165 has very little efficacy at the other subtype(s) of nAChRs responsible for [ 3 H]-dopamine release. Because the ␣4␤2 subtype is a candidate for this role, we examined the behavior of (Ϯ)-UB-165 in a neurochemical assay for this putative subtype. (Lukas et al., 1999) . 
Rb
؉ efflux from thalamic synaptosomes
The efflux of 86 Rb ϩ from preloaded mouse thalamic synaptosomes in response to nicotinic agonists is proposed to reflect the activation of ␣4␤2 nAChRs (Marks et al., 1993 (Marks et al., , 1996 . (Ϯ)-UB-165 was compared with (Ϯ)-epibatidine for its ability to elicit 86 Rb ϩ efflux from this preparation (Fig. 5 A, B) . Although (Ϯ)-epibatidine was a potent and efficacious agonist in this assay (Fig. 5A) , as reported previously (Marks et al., 1996) , (Ϯ)-UB-165 produced very little response when tested over the concentration range examined in the [ 3 H]-dopamine release assay (Fig. 5B) . Indeed, 1 M (Ϯ)-UB-165 elicited Ͻ15% of the maximum 86 Rb ϩ efflux provoked by (Ϯ)-epibatidine. The interpretation that (Ϯ)-UB-165 is a partial agonist with respect to 86 Rb ϩ efflux is supported by the ability of (Ϯ)-UB-165 (1 M) to shift the doseresponse curve for (Ϯ)-epibatidine to the right (Fig. 5A) . Moreover, increasing concentrations of (Ϯ)-UB-165 progressively inhibited the response to a maximally effective concentration of (Ϯ)-epibatidine (100 nM) (Fig. 5B) . The low efficacy of (Ϯ)-UB-165 in eliciting 86 Rb ϩ efflux was verified in rat thalamic synaptosomes (Fig. 5C ). Maximally effective concentrations of (Ϯ)-UB-165, (Ϯ)-anatoxin-a, and (Ϯ)-epibatidine with respect to [ 3 H]-dopamine release were compared. Their relative efficacies in stimulating 86 Rb ϩ efflux resemble their efficacies in evoking ␣-conotoxin-MII-insensitive [ 3 H]-dopamine release (Fig. 4 B) . Indeed, the slight increase in 86 Rb ϩ efflux in response to (Ϯ)-UB-165 was blocked by mecamylamine but was insensitive to ␣-conotoxin-MII (Fig. 5C) .
Activation of inward currents in Xenopus oocytes expressing nAChRs of defined subunit combination
To confirm that UB-165 has low efficacy at ␣4␤2 nAChRs, and to assess its efficacy at other nAChR subtypes, it was examined for its ability to elicit inward currents in Xenopus oocytes expressing pairwise combinations of human ␣ and ␤ subunits, or homooligomeric nAChRs of ␣7 subunits (Fig. 6 ). (Ϯ)-UB-165 was most potent in activating ␣4␤4 and ␣2␤4 nAChRs (EC 50 ϭ 0.05 M), followed by ␣3␤4 (0.27 M), ␣3␤2 (3.9 M), and ␣7 (6.9 M), and was similarly efficacious at these subtypes. In contrast, (Ϯ)-UB-165 failed to elicit significant currents from oocytes expressing ␣4␤2 or ␣2␤2 nAChRs.
Activation of Ca
2؉ fluxes in the SH-SY5Y cell line The functional potency of (Ϯ)-UB-165 at native ␣3-containing nAChRs was investigated in the human neuroblastoma cell line SH-SY5Y. Because this cell line does not express ␣4 subunits, it was used to examine the efficacy of UB-165 at native nAChRs other than the ␣4␤2* subtype. Receptor activation was assayed as an increase in intracellular Ca 2ϩ , measured quantitatively in suspensions of SH-SY5Y cells using fura-2 (Fig. 7) . (Ϯ)-UB-165 and (Ϯ)-anatoxin-a were compared: both agonists increased intracellular Ca 2ϩ , and this effect was totally blocked by 10 M mecamylamine (Fig. 7 A, B) . Determination of dose-response relationships showed that (Ϯ)-UB-165 was more potent than (Ϯ)-anatoxin-a, with EC 50 values of 154 Ϯ 20 and 530 Ϯ 92 nM, respectively (Fig. 7C) . Comparison of maximally effective concentrations of each drug (1 M (Ϯ)-UB-165 and 10 M (Ϯ)-anatoxin-a) showed them to be comparably efficacious in this assay (Fig. 7D) . Increases in intracellular Ca 2ϩ evoked by these maximally stimulating drug concentrations were partially blocked to the same extent by 112 nM ␣-conotoxin-MII (43.9 Ϯ 8.3 and 49.8 Ϯ 10.0% inhibition of (Ϯ)-UB-165-and (Ϯ)-anatoxin-aevoked Ca 2ϩ responses, respectively) (Fig. 7D ).
DISCUSSION
The potent nicotinic agonists epibatidine and anatoxin-a are structurally related in that they both incorporate an azobicyclic core (Fig. 1) ; UB-165 is a hybrid molecule comprising the bulkier values yielded by logistical curve fits were 3.9 M for ␣3␤2 (Ⅺ), 0.05 M for ␣2␤4 (F), 0.27 M for ␣3␤4 (f), 0.05 M for ␣4␤4 (OE), and 6.9 M for ␣7 (ƒ). There was little activation of ␣2␤2 (E) and ␣4␤2 (‚) subtypes. Data points represent mean Ϯ SD of three to six experiments. azobicyclo[4.2.1]nonane moiety of anatoxin-a attached to the chloropyridyl substituent of epibatidine (Wright et al., 1997 (Fig.  2) . It resembles epibatidine in its high degree of discrimination between ␣4␤2* binding sites on the one hand versus ␣7 and muscle sites on the other (Table 1 ). In contrast, UB-165 is more like anatoxin-a with regard to its enantiospecificity (Wright et al., 1997) and its efficacy in upregulating ␣4␤2 nAChRs in M10 cells (Fig. 3) . From these properties and its structural features it was not possible to predict the very low efficacy of UB-165 with regard to striatal [ 3 H]-dopamine release, measured in perf used synaptosome preparations in vitro. Use of the ␣3␤2-selective ␣-conotoxin-M II (C artier et al., 1996) has enabled us to show that this low efficacy of UB-165 arises from its almost complete inability to activate the ␣-conotoxin-MII-insensitive component of nAChR-stimulated [ 3 H]-dopamine release. The failure of UB-165 to activate ␣4␤2*-mediated 86 Rb ϩ efflux from thalamic synaptosomes and to elicit responses in oocytes expressing ␣4␤2 nAChRs provides support for the proposition that presynaptic ␣4␤2* nAChRs on striatal dopaminergic terminals contribute to the nicotinic stimulation of [
3 H]-dopamine release, in addition to ␣3␤2-containing nAChRs (Kulak et al., 1997; Kaiser et al., 1998) . Neurons in the substantia nigra pars compacta of the rat express mRNA for ␣3, ␣4, ␣5, ␣6, ␤2, and ␤3 (Wonnacott, 1997) and possibly ␤4 and ␣7 subunits (Charpantier et al., 1998) , and some or all of these may contribute to nAChRs on dopaminergic terminals in the striatum. The challenge of defining the subunit composition of native nAChRs responsible for particular physiological responses is important for understanding the significance of subunit heterogeneity, rules of assembly, and functional implications arising from receptor subtypes with differing properties. Nicotine-evoked [
3 H]-dopamine release from striatal synaptosomes is absent from ␤2 null mutant mice (Grady et al., 1998) , implicating the ␤2 subunit in all nAChRs in dopaminergic terminals governing this response in the mouse. Sensitivity to ␣-conotoxin-MII (Kulak et al., 1997; Kaiser et al., 1998) , a toxin with specificity for the ␣3␤2 subunit combination expressed in Xenopus oocytes (Cartier et al., 1996; Kaiser et al., 1998 ) is compatible with the requirement for ␤2 to be present. This does not exclude the presence of additional types of subunit in an nAChR containing ␣3 and ␤2 subunits. The restricted distributions of ␣6 and ␤3 mRNA in the CNS, with high expression in the substantia nigra pars compacta Le Novère et al., 1996; Charpantier et al., 1998) , together with the erstwhile "orphan" status of the ␣6 and ␤3 subunits, makes them prime candidates for complex combinations with other subunits such as ␣3 and ␤2 (Fucile et al., 1998; Groot-Kormelink et al., 1998) .
A striking observation from the studies with ␣-conotoxin-MII is its incomplete inhibition of nicotinic agonist-evoked [
3 H]-dopamine release. Kulak et al. (1997) found a block of 34 -49% of (Ϫ)-nicotine-stimulated [
3 H]-dopamine release, whereas Kaiser et al. (1998) reported 56% inhibition of mecamylamine-sensitive release evoked by (Ϯ)-anatoxin-a. The present study reproduces these findings and extends the analysis to other agonists. A partial inhibition (48%) of [ 3 H]-dopamine release evoked by (Ϯ)-epibatidine was observed, whereas the response evoked by (Ϯ)-UB-165 was almost totally inhibited by ␣-conotoxin-MII (Fig. 4) . This suggests that (Ϯ)-UB-165 primarily activates only the ␣-conotoxin-MII-sensitive nAChRs associated with dopaminergic terminals, which accords with an ␣3␤2-containing nAChR. The magnitude of the ␣-conotoxin-MII-sensitive portion of evoked [
3 H]-dopamine release is rather similar between agonists (with the exception of (Ϯ)-epibatidine, for which considerable variability was encountered), whereas the ␣-conotoxin-MIIinsensitive portion varies in the ratio 1:0.88:0.40:0.04 for (Ϯ)-epibatidine, (Ϫ)-nicotine, (Ϯ)-anatoxin-a, and (Ϯ)-UB-165, respectively. This variation in the ␣-conotoxin-MII-insensitive responses to different agonists is largely responsible for their different efficacies with respect to total release (Fig. 4 B) .
The hypothesis, elaborated in the introductory remarks, states that the ␣-conotoxin-MII-insensitive component of nAChRevoked striatal dopamine release is mediated by ␣4␤2* nAChRs. The low efficacy, and complete block by ␣-conotoxin-MII, of UB-165-evoked [ 3 H]dopamine release (Fig. 4) leads to the prediction that (Ϯ)-UB-165 should be a very poor agonist at this receptor subtype. nAChR-evoked 86 Rb ϩ efflux from mouse thalamic synaptosomes is attributed to an ␣4␤2* nAChR (Marks et al., 1993 (Marks et al., , 1996 , and, in agreement with this prediction, UB-165 is a very weak, partial agonist in this assay (Fig. 5) . In rat thalamic synaptosomes, (Ϯ)-epibatidine, (Ϯ)-anatoxin-a, and (Ϯ)-UB-165 stimulated mecamylamine-sensitive 86 Rb ϩ efflux with relative efficacies of 1:0.39:0.08, very comparable to the ratio of efficacies 
